Eupraxia Pharmaceuticals (EPR) Stock Price, News & Analysis

Company Overview

Eupraxia Pharmaceuticals Inc. is a Canadian clinical-stage biotechnology company developing locally acting therapies designed to improve the delivery, duration and tolerability of established medicines. The company’s platform, DiffuSphere, uses biodegradable polymeric microspheres to provide controlled and sustained drug release at targeted sites in the body.

Eupraxia’s lead programs include EP-104IAR, an extended-release intra-articular formulation intended to provide longer-lasting relief for people with knee osteoarthritis, and EP-104GI, an orally administered formulation being developed for gastrointestinal diseases, including eosinophilic esophagitis. The company’s approach is intended to reduce the need for frequent dosing while limiting broader systemic exposure.

Founded in 2011 and headquartered in Victoria, British Columbia, Eupraxia conducts research and clinical development activities in North America. Its pipeline is focused on advancing locally delivered therapies through clinical studies and potential regulatory approval, with programs targeting conditions that may benefit from sustained drug release.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: TSE:EPR
• CIK: N/A
• Web: eupraxia.ca
• Phone: N/A
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A